Long COVID and the Medical System
Given the dysfunction in the American medical system in the response to Acute COVID, it is not surprising that this dysfunction extends to the treatment of Post-Acute Sequela of COVID-19 (PASC) or Long COVID. The problem with the system’s response to the long-term manifestations of the acute disease is the average medical provider in the United States fails to understand the acute disease correctly but clings to a viral pneumonia paradigm offered by administrative medicine and codified into law in the CARES Act in June of 2020.
Despite the rest of the world developing an understanding of COVID-19 as a primarily vascular disease with primary, not secondary, multi-organ system dysfunction, the US physician still adheres to the definition of June 2020. This misunderstanding is manifest now in the outpatient setting in patients seeking help with treatment for symptoms from either vaccine injuries or covid-19 recovery.
Without a proper understanding of the unique pathogenic nature of the spike protein from SARS-CoV2, providers are unable to help patients deal with these lingering and often debilitating conditions. In fact, many medical providers, with unearned hubris, listen to patients and conclude nothing is wrong, and offer them mental counseling. This again is a reminder that the three most important words in medicine, especially in the context of a new disease is ⏤ I don’t know.
Below, we are attaching foundational, peer reviewed articles from the medical literature that definitively explain the unique nature of the spike protein of SARS-CoV2, how it contributes to both the acute disease process but most importantly the long or persistent process and spike protein injuries from vaccinations. Additionally, attaching a lecture for radiologist on COVID-19 lung changes.
References:
SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19 08/21/2021
Lize M. Grobbelaar, Chantelle Venter, Mare Vlok, Malebogo Ngoepe, Gert Jacobus Laubscher, Petrus Johannes Lourens, Janami Steenkamp, Douglas B. Kell, Etheresia Pretorius; SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. Biosci Rep 27 August 2021; 41 (8): BSR20210611. doi: https://doi.org/10.1042/BSR20210611
Coagulopathy during COVID-19 infection: a brief review 09/19/2022
Cunningham, R.M., Johnson Moore, K.L. & Moore, J.S. Coagulopathy during COVID-19 infection: a brief review. Clin Exp Med (2022). https://doi.org/10.1007/s10238-022-00891-4
COVID-19 – A vascular disease 01/2021
Hasan K. Siddiqi, Peter Libby, Paul M Ridker, COVID-19 – A vascular disease, Trends in Cardiovascular Medicine, Volume 31, Issue 1,2021,Pages 1-5, ISSN 1050-1738, https://doi.org/10.1016/j.tcm.2020.10.005
A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
Douglas B. Kell, Gert Jacobus Laubscher, Etheresia Pretorius; A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem J 25 February 2022; 479 (4): 537–559. doi: https://doi.org/10.1042/BCJ20220016
Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC)
Pretorius, E., Venter, C., Laubscher, G.J. et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc Diabetol 21, 148 (2022). https://doi.org/10.1186/s12933-022-01579-5
Oro-Systemic Health Symposium 2022 – Part 3: Graham Lloyd-Jones – The anatomy of COVID-19